AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28254171 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice consistent with both Dietary Approaches to Stop Hypertension (DASH) and dietary portfolio principles (n = 145)
Number of subjects: 919
Study 28254171 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly food provision reflecting this advice (n = 148)
Number of subjects: 919
Study 28254171 — intervention group
Group type: EXPERIMENTAL
Intervention: Food delivery plus advice (n = 140)
Number of subjects: 919
Study 28254171 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (test and control)
Number of subjects: 919
Study 25886941 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week online self-help program aimed at reducing suicidal thoughts
Number of subjects: 570
Study 25886941 — intervention group
Group type: COMPARATOR
Intervention: 6-week attention-matched control program
Number of subjects: 570
Study 25886941 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week online self-help program
Number of subjects: 570
Study 23195393 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5mg)
Number of subjects: 32
Study 23195393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 21075681 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine hydrochloride (serotonin receptor 5-HT2 antagonist)
Number of subjects: 13
Study 21075681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 19548855 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release fampridine (fampridine SR)
Number of subjects: 0
Study 17095643 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g bovine colostrum protein concentrate (CPC)/day
Number of subjects: 29
Study 14507547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy for bulimia nervosa
Number of subjects: 0
Study 14507547 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11054194 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon 0.03 mg/kg
Number of subjects: 46
Study 11054194 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 46
Study 8736249 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course in pre‐ and post‐test counselling
Number of subjects: 0
Study 8736249 — intervention group
Group type: COMPARATOR
Intervention: Usual curriculum (Control)
Number of subjects: 0
Study 1443818 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg.kg‐1 of ketamine
Number of subjects: 26
Study 1443818 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 ml of normal saline)
Number of subjects: 26
Study 2578701 — intervention group
Group type: EXPERIMENTAL
Intervention: High phosphatidylcholine meal
Number of subjects: 11
Study 2578701 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecithin
Number of subjects: 11
Study 2578701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31657615 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplement containing two genera and five species of bacteria
Number of subjects: 95
Study 31657615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 28278361 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised nurse-led home exercise prescription and behavioural support for 12 weeks
Number of subjects: 113
Study 28278361 — intervention group
Group type: COMPARATOR
Intervention: In-centre group exercise training weekly for 6 weeks
Number of subjects: 113
Study 25473823 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent lower-body negative pressure (LBNP) therapy for 60 min daily after exercise
Number of subjects: 24
Study 25473823 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LBNP therapy)
Number of subjects: 24
Study 24350408 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of 1 g every eight hours (q8h) for 24 hours
Number of subjects: 9
Study 24350408 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour infusion of 1 g q8h for 24 hours
Number of subjects: 9
Study 24350408 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour infusion of 2 g q8h for 24 hours
Number of subjects: 9
Study 24350408 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour infusion regimens
Number of subjects: 9
Study 20361330 — intervention group
Group type: EXPERIMENTAL
Intervention: Active disease patients
Number of subjects: 41
Study 20361330 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive disease patients
Number of subjects: 41
Study 20361330 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 41
Study 19604597 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended information regarding new influenza drugs
Number of subjects: 534
Study 19604597 — intervention group
Group type: COMPARATOR
Intervention: Limited information regarding new influenza drugs
Number of subjects: 534
Study 17245718 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha‐2a treatment
Number of subjects: 18
Study 14982567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 2 mg ml(‐1)
Number of subjects: 63
Study 14982567 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 63
Study 11273575 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural work-life intervention allowing up to five days of self-administered sick leave with full financial compensation up to four times a year.
Number of subjects: 265
Study 11273575 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 265
Study 11324075 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital conflict
Number of subjects: 0
Study 11324075 — intervention group
Group type: EXPERIMENTAL
Intervention: Divorce
Number of subjects: 0
Study 11324075 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital problems
Number of subjects: 0
Study 11324075 — intervention group
Group type: EXPERIMENTAL
Intervention: Coparenting, marital happiness, and the institution of marriage
Number of subjects: 0
Study 7697245 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (10(‐9) to 3 x 10(‐5) mmol)
Number of subjects: 16
Study 7697245 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 16
Study 7697245 — intervention group
Group type: COMPARATOR
Intervention: Colchicine
Number of subjects: 16
Study 2575977 — intervention group
Group type: EXPERIMENTAL
Intervention: Epanolol 200mg
Number of subjects: 0
Study 2575977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2575977 — intervention group
Group type: EXPERIMENTAL
Intervention: Epanolol (100mg, 200mg, 300mg, 400mg)
Number of subjects: 0
Study 330885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte-mediated cytotoxicity against T24 cells
Number of subjects: 53
Study 330885 — intervention group
Group type: COMPARATOR
Intervention: Control melanoma cell line (H894)
Number of subjects: 53
Study 31064970 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based KTAS learning program (280 minutes over five weeks, including 40 minutes of orientation and four 60-minute sessions)
Number of subjects: 59
Study 28763712 — intervention group
Group type: EXPERIMENTAL
Intervention: Genium prosthesis
Number of subjects: 20
Study 28763712 — intervention group
Group type: COMPARATOR
Intervention: C-Leg prosthesis
Number of subjects: 20
Study 26268104 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement with micronutrients and plant extracts
Number of subjects: 59
Study 26268104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 23535700 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 141
Study 23535700 — intervention group
Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 141
Study 21572981 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose oral ivermectin (200 microgram/kilogram body weight)
Number of subjects: 90
Study 21572981 — intervention group
Group type: EXPERIMENTAL
Intervention: Double doses of oral ivermectin (given 2 weeks apart)
Number of subjects: 90
Study 21572981 — intervention group
Group type: COMPARATOR
Intervention: 7-day course of oral albendazole (800 mg daily)
Number of subjects: 90
Study 19880462 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antidepressants (various types)
Number of subjects: 0
Study 19880462 — intervention group
Group type: EXPERIMENTAL
Intervention: Policies that improve access to care (e.g., encouraging primary care treatment of depression)
Number of subjects: 0
Study 19880462 — intervention group
Group type: EXPERIMENTAL
Intervention: Policies that promote treatment adherence (e.g., pay-for-performance initiatives)
Number of subjects: 0
Study 16214831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation and antiarrhythmic drug therapy
Number of subjects: 137
Study 16214831 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy alone (control group)
Number of subjects: 137
Study 12525441 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (125 mg/day) + Metformin (1275 mg/day) + Low-dose Oral Contraceptive (ethinyl estradiol 20 microg + gestodene 75 microg)
Number of subjects: 24
Study 12525441 — intervention group
Group type: COMPARATOR
Intervention: Flutamide (125 mg/day) + Metformin (1275 mg/day)
Number of subjects: 24
Study 10592723 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with stable angina pectoris (both with and without previous myocardial infarction)
Number of subjects: 156
Study 10592723 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without previous myocardial infarction
Number of subjects: 156
Study 10592723 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with previous myocardial infarction
Number of subjects: 156
Study 10592723 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 156
Study 8948238 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% carbamide peroxide (CP)
Number of subjects: 0
Study 8948238 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP)
Number of subjects: 0
Study 8948238 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 8948238 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% CP and 10% CP
Number of subjects: 0
Study 1915214 — intervention group
Group type: EXPERIMENTAL
Intervention: Dieting to lose weight
Number of subjects: 4647
Study 1915214 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in organized weight-loss programs
Number of subjects: 4647
Study 1915214 — intervention group
Group type: COMPARATOR
Intervention: Dieters
Number of subjects: 4647
Study 6755046 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA)
Number of subjects: 232
Study 6755046 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine and steroids (control)
Number of subjects: 232
Study 2415436 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course of adenine arabinoside‐5'‐monophosphate (4 weeks)
Number of subjects: 45
Study 2415436 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon (12 weeks)
Number of subjects: 45
Study 2415436 — intervention group
Group type: EXPERIMENTAL
Intervention: Long course of adenine arabinoside‐5'‐monophosphate (7 to 8 weeks)
Number of subjects: 45
Study 2415436 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 29714275 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed strategy to solve stagnation problem of traditional PSO algorithm for phase diversity (PD)
Number of subjects: 0
Study 29714275 — intervention group
Group type: EXPERIMENTAL
Intervention: Redistributing mechanism with randomized Halton sequences
Number of subjects: 0
Study 26596971 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (DAC)
Number of subjects: 206
Study 26596971 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 206
Study 24774721 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated carbon ion radiation therapy (64 GyE in 16 fractions)
Number of subjects: 0
Study 24774721 — intervention group
Group type: COMPARATOR
Intervention: Hypofractionated proton radiation therapy (64 GyE in 16 fractions)
Number of subjects: 0
Study 24774721 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (carbon ion and proton therapy)
Number of subjects: 0
Study 22656399 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mm incision with one-piece intraocular lens (Acrysof SA60AT)
Number of subjects: 18
Study 22656399 — intervention group
Group type: COMPARATOR
Intervention: 3.5 mm incision with three-piece intraocular lens (Tecnis Z9000)
Number of subjects: 18
Study 20052524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18928998 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (1000 mg or less intravenously over 15 minutes, repeated weekly to a maximum of 2500 mg)
Number of subjects: 291
Study 18928998 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate (325 mg orally thrice daily for 6 weeks)
Number of subjects: 291
Study 16032522 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sulphur dioxide concentrations and total suspended atmospheric particles concentrations during the air pollution episode
Number of subjects: 0
Study 12688447 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of caffeine
Number of subjects: 62
Study 12688447 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of caffeine
Number of subjects: 62
Study 12688447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 12688447 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of caffeine
Number of subjects: 62
Study 10687932 — intervention group
Group type: EXPERIMENTAL
Intervention: H.E.L.P.-apheresis
Number of subjects: 27
Study 10687932 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (prednisolone, dextranes, pentoxifyllin)
Number of subjects: 27
Study 8724089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar discectomy
Number of subjects: 126
Study 8724089 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (control)
Number of subjects: 126
Study 1925896 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen receptor positive (ER+) tumors (greater than or equal to 3 femtomoles per milligram cytosol of protein)
Number of subjects: 1392
Study 1925896 — intervention group
Group type: COMPARATOR
Intervention: Estrogen receptor negative (ER-) tumors (less than 3 femtomoles per milligram cytosol protein)
Number of subjects: 1392
Study 1925896 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ER+ tumors
Number of subjects: 1392
Study 6918220 — intervention group
Group type: EXPERIMENTAL
Intervention: Mevinolin 5 mg
Number of subjects: 24
Study 6918220 — intervention group
Group type: EXPERIMENTAL
Intervention: Mevinolin 15 mg
Number of subjects: 24
Study 6918220 — intervention group
Group type: EXPERIMENTAL
Intervention: Mevinolin 50 mg
Number of subjects: 24
Study 6918220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30793994 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intervention: 216 mg caffeine from coffee beverages made from 6 g pure coffee beans (36 mg of caffeine per gram).
Number of subjects: 40
Study 30793994 — intervention group
Group type: COMPARATOR
Intervention: Control: 200 mg lactose without caffeine.
Number of subjects: 40
Study 29395870 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 740
Study 29395870 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (ICBT)
Number of subjects: 740
Study 29395870 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 740
Study 27422890 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GOL)
Number of subjects: 299
Study 24611660 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 22
Study 24611660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 23043923 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqiyangxin Chinese medicine compound combined with cognitive therapy
Number of subjects: 202
Study 23043923 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine combined with cognitive therapy
Number of subjects: 202
Study 20346534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis Relative Wellness Index (developed using desirability functions)
Number of subjects: 109
Study 18444446 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil + Haloperidol 3 mg/h infusion
Number of subjects: 60
Study 18444446 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil + Propofol 25 microg/kg/min infusion
Number of subjects: 60
Study 18444446 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil + Midazolam 0.04 mg/kg/h infusion
Number of subjects: 60
Study 18444446 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil infusion (Control group)
Number of subjects: 60
Study 16129367 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe neutropenia (grade 3-4)
Number of subjects: 1265
Study 16129367 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild neutropenia (grade 1-2)
Number of subjects: 1265
Study 16129367 — intervention group
Group type: EXPERIMENTAL
Intervention: No neutropenia (grade 0)
Number of subjects: 1265
Study 11929373 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI
Number of subjects: 208
Study 11929373 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI with holding chamber (MDI-HC)
Number of subjects: 208
Study 11929373 — intervention group
Group type: COMPARATOR
Intervention: PFM
Number of subjects: 208
Study 11066617 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailing First Look booklet
Number of subjects: 6923
Study 11066617 — intervention group
Group type: COMPARATOR
Intervention: Control group (no booklet mailed)
Number of subjects: 6923
Study 8739145 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatal plate therapy
Number of subjects: 29
Study 8739145 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 1681918 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g intravenously at the time of skin incision (Group I, n = 112)
Number of subjects: 219
Study 1681918 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime 1.5 g intravenously at the time of skin incision, followed by a second dose eight hours later (Group II, n = 107)
Number of subjects: 219
Study 1681918 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (Group I)
Number of subjects: 219
Study 1681918 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime (Group II)
Number of subjects: 219
Study 6627831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 20
Study 6627831 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 20
Study 6627831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen and Acetaminophen (concurrent use)
Number of subjects: 20
Study 31418329 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) training for 8 weeks
Number of subjects: 34
Study 31418329 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 34
Study 30024241 — intervention group
Group type: EXPERIMENTAL
Intervention: Compromise and asymmetric-dominance decoys
Number of subjects: 6312
Study 30024241 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced exposure to candidates' warmth and competence information
Number of subjects: 6312
Study 27774917 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary calcium meal (HDCM; 547 mg DC)
Number of subjects: 16
Study 27774917 — intervention group
Group type: EXPERIMENTAL
Intervention: High supplemental calcium meal (HSCM; 500 mg SC-calcium carbonate)
Number of subjects: 16
Study 27774917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calcium meal (LCM; 42 mg DC)
Number of subjects: 16
Study 25227981 — intervention group
Group type: EXPERIMENTAL
Intervention: Midlife dietary vitamin D intake (quartiles Q4 vs. Q1)
Number of subjects: 1990
Study 22844391 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-item multimedia screening instrument (VS-CMD)
Number of subjects: 85
Study 22844391 — intervention group
Group type: COMPARATOR
Intervention: Text-based agoraphobia items of the PDSS-SR
Number of subjects: 85
Study 20196711 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation from a palliative care team in addition to usual ICU end-of-life care
Number of subjects: 20
Study 20196711 — intervention group
Group type: COMPARATOR
Intervention: Usual ICU end-of-life care without palliative care team consultation
Number of subjects: 20
Study 17933742 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation induced prior to message reception
Number of subjects: 0
Study 17933742 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation induced after message reception
Number of subjects: 0
Study 17933742 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of timing of self-affirmation
Number of subjects: 0
Study 17933742 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 0
Study 15613414 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone patches (300 mcg testosterone over 24 hours, applied twice weekly)
Number of subjects: 52
Study 15613414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 15613414 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone patches
Number of subjects: 52
Study 12215589 — intervention group
Group type: EXPERIMENTAL
Intervention: Echovist-300
Number of subjects: 81
Study 12215589 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 81
Study 9527734 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 30 mg x h(‐1)
Number of subjects: 82
Study 9527734 — intervention group
Group type: COMPARATOR
Intervention: Fat emulsion (Intralipid) 3 ml x h(‐1)
Number of subjects: 82
Study 9527734 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study 7658178 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0
Study 2711539 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration (20 Hz, 20 m/s2 RMS)
Number of subjects: 8
Study 2711539 — intervention group
Group type: COMPARATOR
Intervention: No vibration
Number of subjects: 8